Huahai Pharma's subsidiary achieves trial endpoint for GPP treatment

Zhejiang Huahai Pharmaceutical (SSE: 600521) announced that a pivotal clinical trial of its subsidiary's HB0034 injection has met its primary efficacy endpoint and all key secondary endpoints. The trial focused on treating acute episodes of generalized pustular psoriasis (GPP), a rare and life-threatening skin disease. Results showed that HB0034 significantly cleared skin pustules in patients within one week, compared to the placebo group, with good safety profile. The drug has already been granted Orphan Drug Designation by the U.S. FDA. As of now, the company has invested approximately RMB 21.038 million in the HB0034 injection project.